I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Femoral neck fractures are one of the most common orthopedic injuries in the elderly.\[[@ref1][@ref2][@ref3][@ref4]\] About 1.6 million individuals suffer from femoral neck fractures every year, of which more than 50% are intracapsular fractures.\[[@ref5][@ref6]\] According to several epidemiological studies, the incidence of femoral neck fracture will continue to increase, with an estimated incidence of 6.26 million in 2050.\[[@ref6][@ref7][@ref8]\]

A displaced intracapsular femoral neck fracture is associated with a high incidence of nonunion and femoral head necrosis, as well as a significant mortality and disability.\[[@ref9][@ref10]\]

Although most femoral neck fractures in young, active patients are treated using reduction with internal fixation (IF),\[[@ref11]\] there is conflicting evidence regarding the choice of surgical treatment for elderly patients with displaced intracapsular femoral neck fractures. Indeed, it has frequently been termed "the unsolved fracture."\[[@ref2][@ref4][@ref9]\]

Currently, this type of fracture is typically managed by arthroplasty (AR) or IF.\[[@ref1][@ref4]\] IF, including screw and plate fixation, has been reported to cause minor damage to soft tissue and to have shorter operation times and less intraoperative blood loss when compared with AR.\[[@ref12][@ref13][@ref14]\] However, IF is also related to high morbidity of nonunion and femoral head avascular necrosis (with reported incidences of 20--35%, and 5--30%, respectively).\[[@ref14]\] AR, including hemiarthroplasty (HA) and total hip arthroplasty (THA), entails replacing the femoral head with an artificial hip joint, which avoids the risk of nonunion or femoral head necrosis. The reported advantages of AR also include a low re-operation rate and early functional recovery.\[[@ref14][@ref15][@ref16]\] However, AR involves more extensive soft tissue damage and a high risk of aseptic loosening.\[[@ref1][@ref10][@ref14]\] Several short-to-intermediate term studies and the most recent systematic review indicated that AR may have an advantage over IF in terms of functional outcomes and re-operation rate.\[[@ref9][@ref17]\] However, to our knowledge, to date, very few systematic review or meta-analysis regarding long-term (\>10 years postsurgery) results of AR and IF has been published. Thus, the supposed long-term superiority in the outcome of AR has not yet been clearly demonstrated.

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) for the following purposes: (1) To investigate and compare the short- (\<5 years) and long-term (\>10 years) clinical effectiveness of AR and IF in elderly patients with displaced intracapsular femoral neck fractures, including the rates of complications, mortality, and revision and postoperative functional scores and (2) to do subgroup analysis of THA and HA with IF for further comparison.

M[ethods]{.smallcaps} {#sec1-2}
=====================

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University, School of Medicine, and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines\[[@ref18]\] and the methods established in the *Cochrane Handbook for Systematic Reviews of Interventions* (version 5.0.2).

Literature search {#sec2-1}
-----------------

Three independent investigators (Chen-Yi Ye, An Liu, and Ming-Yuan Xu) searched electronic databases (PubMed, the Cochrane Library, and Embase) with no language restriction through January 2016. The following Medical Subject Headings or key words were used: "femoral neck fracture" or "intracapsular" or "intraarticular" or "cervical" or "subcapital" and "arthroplasty" or "joint replacement" or "total hip arthroplasty" or "THA" or "total joint replacement" or "TJR" or "hemiarthroplasty" or "HA" and "internal fixation" or "IF" or "plate" or "screw." We also manually searched reference lists for additional studies. The Clinical Trial Registry, the Current Controlled Trials databases, and the National Institutes of Health were also searched for unpublished trials and for those in progress.

Inclusion criteria {#sec2-2}
------------------

Two independent reviewers (Chen-Yi Ye and An Liu) screened manuscript titles and abstracts and identified articles that met the following eligibility criteria: (1) Randomized controlled design, (2) direct comparison of the AR and IF techniques reporting clinical outcomes, (3) enrollment of elderly individuals (≥60 years) with an acute displaced intracapsular femoral neck fracture (Garden III and IV classification), and (4) a minimum follow-up of 12 months. We excluded (1) articles that did not satisfy the inclusion criteria, (2) animal studies, cadaver studies, letters, abstracts, case reports, reviews, conference proceedings; (3) studies with no comparative data provided, and (4) studies with follow-up \<1 year.

Data extraction {#sec2-3}
---------------

Three reviewers (Chen-Yi Ye, An Liu, and Ming-Yuan Xu) independently obtained relevant data and assessed accuracy. The following information was extracted from each study: family name of the first author, year of publication, study design, patient demographics (age, gender, interventions, and sample size), length of follow-up, complication rate, mortality rate, revision rate, and postoperative functional scores. We also attempted to contact the corresponding authors to verify the accuracy of the data, as well as to obtain any further data for the analysis.

Quality assessment {#sec2-4}
------------------

Two investigators (Chen-Yi Ye and An Liu) independently assessed the quality of the methodological data included in the studies based on the 12-item scale.\[[@ref19]\] The 12-item scale comprised the following: adequately randomized, allocation concealed, patient blinded, outcome assessor blinded, care provider blinded, similar baseline, similar timing, similar or avoided cofactors, patient compliance, avoided selective reporting, acceptable dropout rate, and intention-to-treat analysis. Divergences were evaluated using kappa test, and consensus was obtained by discussion with the corresponding author (Rong-Xin He).

Statistical analysis {#sec2-5}
--------------------

RevMan software (version 5.3; The Nordic Cochrane Centre, Copenhagen, Denmark) was used to pool the data. STATA 11.0 software (Stata Corp., College Station, TX, USA) was used to evaluate publication bias. *P* ≤ 0.05 was considered statistically significant. Relative risk (*RR*) and 95% confidence intervals (*CI*s) were calculated as summary statistics for dichotomous outcomes, while weighted mean differences (WMDs) or standardized mean differences (SMDs) with 95% *CI*s were calculated for continuous data.\[[@ref20]\] Chi-square test on N − 1 degrees of freedom was used to evaluate statistical heterogeneity, with significance set at 0.05. *I*^2^ (*I*^2^ = \[(*Q* − *df*)/*Q*\] × 100%) was used to evaluate the percentage of the variability in effect estimates according to the heterogeneity. *I*^2^ values of 25%, 50%, and 75% were considered to indicate low, medium, and high heterogeneity, respectively.\[[@ref21]\] If no statistical heterogeneity was detected (*I*^2^ \< 50%), a fixed-effects model was used; otherwise, we used a random-effects model. If substantial heterogeneity across studies (*I*^2^ \> 50%) was detected, *post hoc* sensitivity analysis was performed by omitting the outlier studies to determine the sources of heterogeneity. Begg\'s rank correlation test and Egger\'s regression test were used to assess publication bias.

R[esults]{.smallcaps} {#sec1-3}
=====================

Literature search {#sec2-6}
-----------------

In total, the search identified 5106 candidate publications; however, 5083 were excluded due to duplications, nonrelevance, or because they were not RCTs. After assessing the 23 potentially relevant articles, eight RCTs involving 2206 patients met the inclusion criteria.\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29]\] The primary reasons for exclusion were as follows: six were review articles,\[[@ref11][@ref30][@ref31][@ref32][@ref33][@ref34]\] six reported data that did not pertain to intracapsular hip fractures,\[[@ref3][@ref15][@ref35][@ref36][@ref37][@ref38]\] one was a correspondence letter,\[[@ref39]\] and two studies were excluded because they were not RCTs.\[[@ref40][@ref41]\] Details of the selection process are shown in [Figure 1](#F1){ref-type="fig"}. The weighted kappa for the agreement on eligibility between the reviewers was 0.88 (95% *CI* \[0.83--0.94\]).

![A Preferred Reporting Items for Systematic Reviews and Meta-analyses flowchart illustrated the selection of studies included in our systematic review.](CMJ-129-2630-g001){#F1}

Study characteristics {#sec2-7}
---------------------

The characteristics and quality assessment results of the eight RCTs are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Five studies compared HA with IF,\[[@ref23][@ref24][@ref26][@ref27][@ref29]\] two studies compared both THA and HA with IF,\[[@ref22][@ref25]\] and one study compared THA and IF.\[[@ref28]\] The mean length of follow-up ranged from 1 to 17 years. In total, 2206 patients were included in the analysis: 435 males and 1771 females aged from 62 to 103 years. Of these, 1184 patients received AR and 1022 patients received IF.

###### 

Methodological quality of the included studies based on the 12-item scoring system

  Study                                     Randomized adequately\*   Allocation concealed   Patient blinded   Care provider blinded   Outcome assessor blinded   Acceptable dropout rate^†^   ITT analysis^‡^   Avoided selective reporting   Similar baseline   Similar or avoided cofactor   Patient compliance^§^   Similar timing   Quality^\|\|^
  ----------------------------------------- ------------------------- ---------------------- ----------------- ----------------------- -------------------------- ---------------------------- ----------------- ----------------------------- ------------------ ----------------------------- ----------------------- ---------------- ---------------
  Ravikumar and Marsh, 2000^\[[@ref22]\]^   Yes                       Yes                    Unclear           Unclear                 Unclear                    Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              High
  Davison *et al*., 2001^\[[@ref23]\]^      Yes                       Yes                    Unclear           Unclear                 Unclear                    Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              High
  Parker *et al*., 2002^\[[@ref24]\]^       Yes                       Yes                    Unclear           Unclear                 Unclear                    Yes                          Unclear           Unclear                       Unclear            Yes                           Yes                     Yes              Moderate
  Keating *et al*., 2006^\[[@ref25]\]^      Yes                       Yes                    Unclear           Unclear                 Yes                        Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              High
  Frihagen *et al*., 2007^\[[@ref26]\]^     Yes                       Yes                    Unclear           Unclear                 Unclear                    Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Unclear          Moderate
  Parker *et al*., 2010^\[[@ref27]\]^       Yes                       Yes                    Unclear           Unclear                 Unclear                    Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              High
  Chammout *et al*., 2012^\[[@ref28]\]^     Yes                       No                     No                No                      No                         Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              Moderate
  Parker, 2015^\[[@ref29]\]^                Yes                       Yes                    Unclear           Yes                     Unclear                    Yes                          Unclear           Unclear                       Yes                Yes                           Yes                     Yes              High

\*Only if the method of sequence made was explicitly introduced could get a "yes;" sequence generated by "dates of admission" or "patients' number" receives a "no;" ^†^Dropout rate \<20% could get a "yes," otherwise "no;" ^‡^ITT: Intention-to-treat, only if all randomized participants were analyzed in the group they were allocated to could receive a "yes;" ^§^More than 75% of the patients wore respective devices for at least 3 weeks means "yes," otherwise "no;" ^\|\|^"Yes" items \>7 means "high"; "Yes" items more than 4 but no more than 7 means ''Moderate''; 'Yes" items \<4 means ''Low''.

###### 

Study characteristics and details of interventions of the included studies

  Studies                                  Study design   Age            Gender male/female   Number of patients   Interventions   Follow-up (years)   Prostheses                                                       
  ---------------------------------------- -------------- -------------- -------------------- -------------------- --------------- ------------------- ------------ ------------- ---- -------------------------------- -------------------------------------
  Ravikumar and Marsh 2000^\[[@ref22]\]^   RCT            81.55 ± 3.36   79.73 ± 2.49         27/244               180             91                  HA/THA       Screw/plate   13   HA: Austin Moore/THA: Howse II   Sliding compression screw plate
  Davison*et al*., 2001^\[[@ref23]\]^      RCT            75.48 ± 1.61   73 ± 1.75            67/213               187             93                  HA           Screw/plate   5    Thompson HA/Monk bipolar HA      Sliding compression screw plate
  Parker*et al*., 2002^\[[@ref24]\]^       RCT            82.4 ± 7.5     82.2 ± 8             91/364               229             226                 HA           Screw         3    Austin Moore                     AO cancellous screws
  Keating*et al*., 2006^\[[@ref25]\]^      RCT            75.32 ± 6.62   74.68 ± 6.74         81/286               180             187                 HA/THA       Screw/plate   2    NA                               NA
  Frihagen*et al*., 2007^\[[@ref26]\]^     RCT            82.5 ± 7.32    83.2 ± 7.65          57/165               110             112                 HA           Screw         2    Charnley--Hastings bipolar HA    Olmed screw
  Parker*et al*., 2010^\[[@ref27]\]^       RCT            82.4 ± 7.5     82.2 ± 8             91/364               229             226                 HA           Screw         11   Austin Moore                     AO cancellous screws (Stratec Ltd.)
  Chammout*et al*., 2012^\[[@ref28]\]^     RCT            78 ± 6.25      79 ± 6               21/79                43              57                  THA          Screw         17   Bi-metric                        Olmed screw
  Parker, 2015^\[[@ref29]\]^               RCT            81.2 ± 6.5     81.5 ± 8             0/56                 26              30                  HA           Screw/plate   1    Exeter trauma stem               Targon femoral plate

AR: Arthroplasty; IF: Internal fixation; THA: Total hip arthroplasty; HA: Hemiarthroplasty; NA: Not applicable; RCT: Randomized controlled trial.

Outcome measures {#sec2-8}
----------------

The pooled results are shown in [Table 3](#T3){ref-type="table"}.

###### 

The statistical comparison in outcomes between AR and IF

  Outcomes                             Studies (*n*)   Participants   Event (*n*/*N*)   Mean (95% *CI*)   *I*^2^ (%)             *P*   
  ------------------------------------ --------------- -------------- ----------------- ----------------- ---------------------- ----- -----------
  Total mortality rate - *RR*          6               1826           587/954           501/872           1.02 (0.96, 1.08)      25    0.63
   Mortality rate within 1 year        5               1284           167/732           126/552           1.06 (0.86, 1.30)      0     0.58
   Mortality rate within 2 years       4               1324           221/706           180/618           1.15 (0.98, 1.34)      0     0.08
   Mortality rate \>10 years           2               726            362/409           290/317           0.97 (0.90, 1.06)      59    0.52
  Total re-operation rate - *RR*       6               1738           63/864            378/874           0.17 (0.13, 0.22)      10    \<0.00001
   Re-operation rate within 1 year     2               336            3/213             28/123            0.07 (0.02, 0.22)      0     \<0.00001
   Re-operation rate within 2 years    3               869            28/477            138/392           0.19 (0.13, 0.27)      0     \<0.00001
   Re-operation rate \>10 years        2               371            39/223            67/148            0.44 (0.31, 0.62)      0     \<0.00001
  Total revision rate - *RR*           7               1838           33/907            314/931           0.11 (0.08, 0.16)      35    \<0.00001
   Revision rate within 1 year         2               327            16/206            31/121            0.29 (0.16, 0.52)      30    \<0.00001
   Revision rate within 2 years        2               502            5/297             39/205            0.08 (0.03, 0.21)      0     \<0.00001
   Revision rate \>10 years            2               555            16/272            112/283           0.15 (0.09, 0.25)      8     \<0.00001
  Total complication rate - *RR*       5               1415           177/742           294/673           0.56 (0.38, 0.80)      76    \<0.01
  Total patients with pain - *RR*      4               776            53/423            105/353           0.31 (0.23, 0.41)      30    \<0.00001
   Patients with pain within 1 year    2               551            97/409            69/317            0.50 (0.07, 3.55)      0     0.16
   Patients with pain within 2 years   3               869            23/339            39/338            0.70 (0.37, 1.34)      0     \<0.05
   Patients with pain \>10 years       2               371            47/223            73/148            0.83 (0.32, 2.17)      38    \<0.00001
  Infection rate - *RR*                6               1598           36/832            30/766            1.06 (0.66, 1.71)      15    0.81
   Infection rate within 1 year        2               551            1/367             1/184             0.50 (0.07, 3.55)      0     0.49
   Infection rate within 2 years       3               869            14/477            20/392            0.70 (0.37, 1.34)      0     0.28
   Infection rate \>10 years           2               371            10/223            7/148             0.83 (0.32, 2.17)      0     0.7
  Deep vein thrombosis rate - *RR*     4               1100           7/545             12/555            0.64 (0.27, 1.51)      0     0.31
  Harris score within 1 year - WMD     2               589            NA/290            NA/299            6.93 (4.33, 9.53)      0     \<0.00001
  Harris score within 2 years - WMD    2               589            NA/290            NA/299            3.60 (0.73, 6.47)      0     \<0.05
  Operation time - WMD                 3               878            NA/435            NA/443            19.66 (15.44, 23.87)   58    \<0.00001
  Blood loss - SMD                     2               677            NA/339            NA/338            1.87 (1.69, 2.05)      0     \<0.00001
  Hospital stay -WMD                   3               558            NA/323            NA/235            1.09 (0.46, 1.73)      25    \<0.01

AR: Arthroplasty; IF: Internal fixation; *RR*: Risk ratio; SMD: Standardized mean difference; WMD: Weighted mean difference; NA: Not applicable; *CI*: Confidence interval.

**Mortality of 30 days, 3−6 months, and up to 1, 2, and 10 years**

No statistically significant difference was found regarding mortality between AR and IF at 30 days and 3−6 months postoperatively (*RR* = 1.27, 95% *CI* = 0.74−2.17; *P* = 0.38 and *RR* = 1.21, 95% *CI* = 0.88−1.65; *P* = 0.25, respectively). In addition, there was also no statistically significant difference between groups in 1 or 2 years postoperatively (*RR* = 1.06, 95% *CI* = 0.86−1.30; *P* = 0.58 and *RR* = 1.15, 95% *CI* = 0.98−1.34; *P* = 0.08, respectively). No evidence of significant heterogeneity (*I*^2^ = 0) was observed within any subgroup, except a low heterogeneity (*I*^2^ = 59%) regarding the mortality rate of \>10 years postoperatively. However, due to the limited number of available studies (*n* = 2), a sensitivity analysis was not possible.

**Re-operation**

The incidence of re-operations (including revision surgery, drainage of infected implants, fixation of periprosthetic fractures, removal of implants, reduction of dislocation, and excision AR) was reported in six studies (1738 patients, 441 events). These studies included 864 ARs and 874 IFs (re-operation events occurred in 63 and 378 cases, respectively). The pooled *RR* for re-operation after AR compared with IF was 0.17 (95% *CI* = 0.13−0.22; *P* \< 0.00001, *I*^2^ = 10%). The re-operation rate following AR was significantly lower than for IF at 1, 2, and \>10 years postoperatively (*P* \< 0.00001). No evidence of heterogeneity was observed (*I*^2^ = 0%).

**Revision**

The total revision rates in the AR and IF groups were 33/907 and 314/931, respectively. The pooled *RR* for revision after AR versus IF was 0.11 (95% *CI* = 0.08--0.16; *P* \< 0.0001, *I*^2^ = 35%). AR was associated with significantly lower revision rates than IF at 1, 2, and \>10 years postoperatively (*P* \< 0.00001). No evidence of significant heterogeneity was observed (*I*^2^ \< 50%).

**Complications**

Details of complications are shown in [Table 3](#T3){ref-type="table"}. AR was associated with significantly fewer total complications (fixation failure, femoral head necrosis, nonunion, dislocation, and perioperative complications, including deep wound infection, deep venous thrombosis (DVT), myocardial infarction, pulmonary embolism, and stroke) than IF (*RR* = 0.56; 95% *CI* = 0.38−0.80; *P* \< 0.01, *I*^2^ = 76%). No significant difference in infection or DVT rates was found (*P* \> 0.05, *I*^2^ = 0). A sensitivity analysis was performed for the results of total complication rates, which yielded similar results to those obtained when all studies were analyzed simultaneously.

**Pain**

Pain was reported in four studies (776 patients, 158 events). Pain was more frequent in patients treated with IF (105/353, 29.7%) than those treated with AR (53/423, 12.5%) (*RR* = 0.31; 95% *CI* = 0.23−0.41; *P* \< 0.00001, *I*^2^ = 30%). Subgroup analysis regarding the length of follow-up showed no statistically significant difference between AR and IF in 1 year postoperatively. However, patients treated with AR group had significantly less pain than those receiving IF at 2 and \>10 years after the operation (*P* \< 0.05). Heterogeneity was not significant (*I*^2^ \< 50%) \[[Figure 2](#F2){ref-type="fig"}\].

![Relative risk and 95% confidence interval for the number of patients with moderate-to-severe pain.](CMJ-129-2630-g002){#F2}

**Functional scores**

Functional scores were reported in two studies including 589 patients. The pooled WMDs of mean Harris hip score for AR versus IF was 6.93 (95% *CI* = 4.33−9.53; *P* \< 0.00001, *I*^2^ = 0) and 3.60 (95% *CI* = 0.73−6.47; *P* \< 0.05, *I*^2^ = 0) at 1 and 2 years after the operation, respectively. Patients treated with AR appear to have had better postoperative function than those treated with IF.

**Other data**

IF was associated with significantly shorter operation times (WMD, 19.66; 95% *CI* = 15.44--23.87; *P* \< 0.00001, *I*^2^ = 58%), less blood loss (SMD, 1.87, 95% *CI* = 1.69--2.05; *P* \< 0.00001, *I*^2^ = 0%), and fewer in-hospital days (WMD, 1.09; 95% *CI* = 0.46--1.73; *P* \< 0.01, *I*^2^ = 25%) when compared with AR. No statistically significant difference was found between AR and IF.

**Subgroup analyses**

Results of subgroup analyses of the statistical comparison in outcomes between HA, THA, and IF are shown in [Table 4](#T4){ref-type="table"}. Both HA and THA were superior to IF in terms of re-operation, revision, and pain, whereas IF was associated with significantly shorter operation times, hospital stays, and less blood loss. No statistically significant difference in mortality, infection, or deep vein thrombosis rates was found.

###### 

Subgroup analysis of the statistical comparison in outcomes between HA, THA, and IF

  Outcomes                                      Studies   Participants   Event     Mean (95% *CI*)   *I*^2^ (%)           *P*   
  --------------------------------------------- --------- -------------- --------- ----------------- -------------------- ----- -----------
  Subgroup analysis between HA and IF                                                                                           
   Total mortality rate -*RR*                   6         1697           478/892   428/805           1.06 (0.99, 1.14)    15    0.11
   Total re-operation rate - *RR*               6         1600           57/795    351/805           0.16 (0.13, 0.21)    15    \<0.00001
   Total revision rate - *RR*                   6         1695           29/892    266/803           0.10 (0.07, 0.15)    0     \<0.00001
   Total complications - *RR*                   4         1088           117/431   191/435           0.55 (0.37, 0.82)    36    \<0.01
   Total patients with pain - *RR*              3         859            62/430    89/429            0.69 (0.54, 0.89)    0     \<0.01
   Infection rate - *RR*                        5         1506           30/797    24/709            1.23 (0.73, 2.08)    27    0.44
   Deep vein thrombosis - *RR*                  4         962            3/476     9/486             0.45 (0.15, 1.33)    0     0.15
   Harris hip score within 2 years - WMD        2         434            NA/212    NA/222            3.21 (−0.12, 6.53)   0     0.06
   Operation time - WMD                         2         285            NA/137    NA/148            0.59 (0.11, 1.08)    62    \<0.05
   Blood loss - SMD                             2         677            NA/339    NA/338            1.87 (1.69, 2.05)    0     \<0.00001
   Hospital stay - WMD                          3         558            NA/323    NA/235            1.09 (0.46, 1.73)    25    \<0.01
  Subgroup analysis between THA and IF - *RR*                                                                                   
   Total mortality rate                         2         318            78/158    91/160            0.87 (0.76, 1.01)    0     0.06
   Total re-operation rate                      3         418            23/201    94/217            0.28 (0.19, 0.42)    17    \<0.00001
   Total revision rate                          3         418            10/201    78/217            0.15 (0.08, 0.27)    45    \<0.00001
   Total complications                          3         418            33/158    35/160            0.72 (0.38, 1.35)    0     0.81
   Total patients with pain                     2         280            6/132     73/148            0.09 (0.04, 0.19)    0     \<0.00001
   Infection rate                               3         418            6/201     11/217            0.59 (0.23, 1.54)    0     0.28

HA: Hemiarthroplasty; THA: Total hip arthroplasty; AR: Arthroplasty; IF: Internal fixation;*RR*: Risk ratio; SMD: Standardized mean difference; WMD: Weighted mean difference; NA: Not applicable; *CI*: Confidence interval.

**Publication bias**

No substantial asymmetry was identified using Begg\'s rank correlation test (*Z* = 0.75, *P* = 0.452) or Egger\'s regression test (*t* = 0.17, *P* = 0.874).

D[iscussion]{.smallcaps} {#sec1-4}
========================

In the absence of a new study of the long-term efficacy for AR and IF, we conducted this systematic review and meta-analysis of eight RCTs, trying to provide updated evidence by comparing the short- and long-term clinical effectiveness of AR and IF for elderly patients with displaced intracapsular femoral neck fractures. The pooled results of long-term follow-up suggest that relative to IF, AR leads to lower total rates of re-operation, revision, and major method-related complications, without increasing the mortality. Moreover, patients treated with AR seemed to suffer less persistent pain and possibly have better postoperative function than those receiving IF.

The most recent previous systematic review about IF versus AR for adults with intracapsular proximal femoral fractures\[[@ref9]\] showed that IF was associated with less operative trauma but had an increased risk of re-operation (40% vs. 11%; *RR* = 3.22, 95% *CI* = 2.31--4.47). This study also found that IF has a significantly shorter length of operation, less intraoperative blood loss, and less incidence of deep wound infection than AR. No significant difference regarding hospital stay or mortality was observed.\[[@ref9]\] However, due to the limited number of available studies, comparisons regarding long-term re-operation rates, revision rates, and patients with persistent pain between AR and IF were not made. Because AR was not widely used in the 1990s for femoral neck fractures, we excluded RCTs published before 2000. Moreover, we included all RCTs with long-term follow-up (\>10 years)\[[@ref22][@ref27][@ref28]\] and all RCTs focusing only on elderly patients. Similar results to the previous study were found regarding short-term mortality, re-operation, incidence of persistent pain, and perioperative parameters, including the length of operation and intraoperative blood loss. However, our study indicated the long-term superiority of AR in terms of re-operation, revision, and the incidence of persistent pain. No significant difference regarding infection rate was observed.

The long-term re-operation rate is one of the most important parameters for evaluating AR and IF. It is difficult to pool data regarding re-operation because of the varied definitions across studies. To manage this, we subdivided re-operations into two categories: total re-operation rates and revision rates. The large number of patients requiring a second operation is of concern. Re-operation rates between 30% and 50% have been reported after IF for displaced intracapsular femoral neck fractures.\[[@ref14][@ref42]\] The previous review article indicated that IF was associated with an increased risk of re-operation when compared with AR (40% vs. 11%).\[[@ref9]\] In this study, similar results for IF were observed (43.2%), while the observed re-operation rate in the AR group was lower (7.3%). Our study showed that AR might not only lead to fewer long-term re-operations but also fewer revisions than IF. However, some of these patients had more than one re-operation, and the times of re-operations were often not reported. Moreover, as noted by Parker,\[[@ref29]\] the application of newer implants in IF may be associated with a reduction in the revision rate. More RCTs directly comparing different IF implants are needed in the future, with both short- and long-term follow-ups.

The long-term pain rate was significantly higher for IF group than AR. By conducting a subgroup analysis, we found that this difference existed at 2 and \>10 years postoperatively while no statistically significant difference was observed in the 1^st^ year after the primary surgery. The reasons, we suggest, may be largely related to the high incidence of avascular necrosis, nonunion, and mechanical failure of implants following IF.\[[@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29]\] Attempting to minimize the influence of different descriptions of pain across studies, the analyses only documented the number of patients with persistent pain; results based on different scoring systems were not pooled.

Although IF was favored in terms of perioperative parameters, there was no significant difference between AR and IF with respect to mortality at any follow-up time point, consistent with the results of Parker and Gurusamy.\[[@ref9]\] The reason, we suggest, may be the study population; we included only elderly patients, with a mean age of \>70 years, meaning that most of the patients (1088 of 1826 patients in six studies, 59.58%) were lost because of natural death. For the same reason, comparison of long-term mortality rates is of little value.\[[@ref17]\]

With respect to total complications, including fixation failure, femoral head necrosis, nonunion, dislocation, and perioperative complications, the present study indicated a lower total complication rate following AR than IF. The avoided risk of nonunion or femoral head necrosis and the reported low re-operation rate of AR may contribute to this.\[[@ref14][@ref15][@ref16]\] However, the subgroup analysis revealed that this difference was specific to THA versus IF. Further well-designed RCTs of high quality are needed.

The pooled data for the Harris hip score at 1 and 2 years after surgery showed that AR may increase the chances of early functional recovery. The Harris hip score difference between AR and IF in the present study was 3.6 points at 2 years postoperatively, which is less than the minimal clinically important difference of 4 points,\[[@ref43]\] suggesting AR might not be preferential to IF in terms of overall functional recovery.

We acknowledge that our study has several limitations. The limitations include: (1) The limited number of RCTs comparing AR with IF with long-term follow-up. Our systematic review and meta-analysis included eight RCTs; three reported results with a follow-up of \>10 years. Future RCTs with large samples and long-term follow-up are still needed, (2) the wide range of implants used both for IF and AR may increase bias. However, this variety of usage is likely to continue in clinical practice. Future studies based on different types of prostheses would be of interest, (3) information on cost-effectiveness and long-term function was not available, (4) some caution is needed when considering the results of this study because of the age and the underlying diseases of the included patients, which may influence the results such as infection rate or deep vein thrombosis rates. Future comprehensive analyses regarding the optimal treatment for displaced intracapsular femoral neck fractures are still needed. Despite these limitations, the study does provide useful insights into the long-term effectiveness of AR and IF for displaced intracapsular femoral neck fractures in the elderly.

In conclusion, based on our analysis, we recommend that AR should be used as the primary treatment for displaced intracapsular femoral neck fractures in the elderly. However, IF may be appropriate for those who are very frail.
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